Brainomix joins forces with Boehringer Ingelheim to help save stroke victims
Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
Salunda – IGas trial proves the measure of success for hand-held drilling fluid sensor
AN initial field trial of an advanced hand-held analyser has revealed its potential for the rapid and effective testing and measurement of oil and gas drilling fluids. Independent oil and gas exploration and production company IGas Energy plc… Read More
Brainomix – International Journal of Stroke Publication
Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and… Read More
Brainomix – Parkwalk closes follow-on investment
We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses… Read More
Salunda – Parkwalk follow-on Investment
We have recently closed an investment in Salunda for the Parkwalk Opportunities Fund. Salunda develops robust, contactless sensors for use in very harsh environments. The company’s sensor technology detects position and speed, and measures the composition of fluids…. Read More
Isis Innovation event at the Royal Society of Chemistry
Huge thank you to Isis Innovation for hosting an excellent evening at the Royal Society of Chemistry: Pitches were made by four inspiring potential investee companies for the University of Oxford Isis Fund III, which we hope to… Read More
Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients
Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The… Read More
Parkwalk closes Bounts investment
We are pleased to announce that the University of Oxford Isis Fund I has closed its final investment into Bounts, an Isis software incubator spin-out company. Bounts is a digital health platform and app that has partnered with… Read More
Brainomix – Positive endovascular trial uses ASPECTS
A seminal paper was published in the New England Journal of Medicine describing the results of the ESCAPE trial for endovascular treatment of stroke patients. This study shows that rapid endovascular treatment leads to significantly improved functional outcomes… Read More
TheySay – University of Oxford Isis Fund I Investment
Parkwalk have recently closed an investment in TheySay for the University of Oxford Isis Fund I. TheySay brings to the market ground-breaking research in computational linguistics from the University of Oxford. Impartial bench-marking studies have been carried out by three leading… Read More
Salunda – University of Oxford Isis Fund I Investment
We have recently closed an investment in Salunda for the University of Oxford Isis Fund I. Salunda develops robust, contactless sensors for use in very harsh environments. The company’s sensor technology detects position and speed, and measures the… Read More
Brainomix – wins ACES award for ICT
University of Oxford Isis Fund I and Parkwalk portfolio company Brainomix wins ACES entrepreneurship prize which rewards companies working in health and environment: BERLIN – 7 October 2014. Spin-outs from Germany, Switzerland and the UK won the ACES… Read More
Brainomix – University of Oxford Isis Fund I and Parkwalk investment
We have recently closed an investment in Brainomix for the University of Oxford Isis Fund I and Parkwalk Funds. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for… Read More
Oxtex – University of Oxford Isis Fund I investment
We have recently made an investment in Oxtex for the University of Oxford Isis Fund I. Oxtex has developed a surgical implant device which addresses the problem created by the lack of sufficient skin in areas requiring reconstructive surgery. Oxtex… Read More
Oxford University Innovation – the new name for Isis Innovation
Isis Innovation will be renamed Oxford University Innovation, in order to enhance the already strong links between Isis Innovation and the University. This will strengthen awareness of the company and its services within the wider University, and better… Read More
Posted on June 29, 2016
Fund Managers Comments
Fund Manager's Comments, Oxford, UoOIF, UoOIF I, UoOIF II, UoOIF III